Call us +91 -7376325889/ 7376335889
Mail
Support
Partners
Careers
Knowledge Center
Downloads
Margin Calculator
Equity
F&O
MF
Online Trading
Open an Account
Back Office
Apply IPO
ABOUT US
SERVICES
MARKETS
Equity
Derivatives
Mutual Fund
IPO
PORTFOLIO
OUR RECOMMENDATIONS
CONTACT US
CALCULATORS
MENU
×
HOME
SERVICES
MARKETS
PORTFOLIO
OUR RECOMMENDATIONS
ABOUT US
SERVICES
CONTACT US
CALCULATORS
Online Trading
Open an Account
Back Office
Apply IPO
Equity Analysis
Company Profile
Price
Volume
Analysis
Company Profile
News Analysis
Corporate Action
Other Markets
Detailed Quotes
Detailed Quotes
Company Snapshot
Company Background
Board of Directors
Profit & Loss
Balance Sheet
Quarterly Results
Key Financial Ratios
Share Holding Pattern
Directors Report
Score Board
MF Holdings
Name Change
Company News
Peer Comparison
Monthly High / Low
Price Chart
Consolidated Quarters
FII Holding
Simple & CAGR Growth
Deliverable Volumes
Company News
Windlas Biotech Ltd
Industry : Pharmaceuticals - Indian - Formulations
BSE Code
ISIN Demat
Book Value(
)
543329
INE0H5O01029
215.4715093
NSE Symbol
P/E(TTM)
Mar.Cap(
Cr.)
WINDLAS
39.26
2338.43
EPS(TTM)
Face Value(
)
Div & Yield %:
28.5
5
0.49
Back
Prudent Corporate Advisory Services Ltd
Prudent Corporate Advisory Services consolidated net profit rises 69.36% in the September 2024 quarter
Oct 30,2024
Net profit of Prudent Corporate Advisory Services rose 69.36% to Rs 51.52 crore in the quarter ended September 2024 as against Rs 30.42 crore during the previous quarter ended September 2023. Sales rose 50.54% to Rs 286.08 crore in the quarter ended September 2024 as against Rs 190.04 crore during the previous quarter ended September 2023.
Particulars
Quarter Ended
Sep. 2024
Sep. 2023
% Var.
Sales
286.08
190.04
51
OPM %
24.03
22.71
-
PBDT
76.02
46.72
63
PBT
69.31
40.59
71
NP
51.52
30.42
69